Active Recombinant Human JAK2 protein, GST-tagged
Cat.No. : | JAK2-336H |
Product Overview : | Recombinant Human JAK2(804-end) fused with GST tag at N-terminal was expressed in Insect cells. |
- Specification
- Gene Information
- Related Products
Description : | JAK2 is a member of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. JAK2 has two near-identical phosphate-transferring domains. One domain exhibits the kinase activity while the other stabilizes the JAK conformational structure. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. |
Source : | Insect cells |
Species : | Human |
Tag : | GST |
Form : | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. |
Bio-activity : | 145 nmol/min/mg |
Molecular Mass : | ~63 kDa |
Purity : | >70% |
Applications : | Kinase Assay, Western Blot |
Storage : | Store product at –70 centigrade. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. |
Concentration : | 0.1 ug/ul |
Gene Name : | JAK2 Janus kinase 2 [ Homo sapiens ] |
Official Symbol : | JAK2 |
Synonyms : | JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3; |
Gene ID : | 3717 |
mRNA Refseq : | NM_004972 |
Protein Refseq : | NP_004963 |
MIM : | 147796 |
UniProt ID : | O60674 |
Chromosome Location : | 9p24 |
Pathway : | Adipocytokine signaling pathway, organism-specific biosystem; Adipocytokine signaling pathway, conserved biosystem; CXCR4-mediated signaling events, organism-specific biosystem; Chemokine signaling pathway, organism-specific biosystem; Chemokine signaling pathway, conserved biosystem; Cholinergic synapse, organism-specific biosystem; Cytokine Signaling in Immune system, organism-specific biosystem; |
Function : | ATP binding; SH2 domain binding; growth hormone receptor binding; heme binding; histone binding; histone kinase activity (H3-Y41 specific); interleukin-12 receptor binding; non-membrane spanning protein tyrosine kinase activity; nucleotide binding; protein binding; protein kinase activity; protein kinase binding; protein tyrosine kinase activity; protein tyrosine kinase activity; receptor binding; |
Products Types
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionJAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.
Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.
JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.
JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.
JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.
Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.
Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).
Customer Reviews (3)
Write a reviewQuick response from customer service.
Product performed as expected.
Satisfied with product quality.
Ask a Question for All JAK2 Products
Required fields are marked with *
My Review for All JAK2 Products
Required fields are marked with *
Inquiry Basket